```html

Keratoconjunctivitis Sicca (Dry Eye) – A Complete Medical Guide

Overview

Keratoconjunctivitis sicca (KCS), commonly called dry eye disease, is a chronic, multifactorial disorder of the ocular surface in which there is an imbalance between the production and drainage of the tear film. This leads to tear film instability, inflammation, and damage to the cornea and conjunctiva.

Anyone can develop dry eye, but it is most prevalent among:

• Adults over age 50 (prevalence rises to 20‑30% in this group)<sup>1</sup>
• Women (approximately 2‑3 times more common than men) <sup>2</sup>
• Individuals who spend many hours in front of screens or in low‑humidity environments
• Patients with autoimmune diseases such as Sjögren’s syndrome, rheumatoid arthritis, or lupus

Global estimates suggest that 5‑30% of the population suffers from some degree of dry eye, making it one of the most common ocular complaints worldwide<sup>3</sup>.

Symptoms

Dry eye symptoms can be subtle at first and may fluctuate throughout the day. Common complaints include:

Ocular Discomfort

• Burning or stinging sensation – feeling like something is in the eye.
• Foreign‑body sensation – often described as “sand in the eye.”
• Itching or gritty feeling.
• Eye fatigue after reading, computer work, or driving.

Visual Disturbances

• Blurry vision that improves with blinking.
• Fluctuating vision, especially in low‑humidity or windy conditions.
• Increased glare sensitivity.

Tear Film Abnormalities

• Excessive tearing (reflex tearing) as the eye tries to compensate for dryness.
• Stringy, mucous‑like discharge.

Other Signs

• Redness of the conjunctiva.
• Sensitivity to light (photophobia).
• Difficulty wearing contact lenses.
• Crusting of eyelids upon waking.

Causes and Risk Factors

Dry eye is usually the result of either decreased tear production, excessive tear evaporation, or a combination of both.

Decreased Tear Production

• Age‑related lacrimal gland decline – natural atrophy of tear‑producing tissue.
• Autoimmune disorders – Sjögren’s syndrome (the classic cause), rheumatoid arthritis, lupus.
• Medications – antihistamines, decongestants, antidepressants, beta‑blockers, isotretinoin.
• Ocular surgeries – LASIK, cataract extraction can temporarily or permanently affect tear innervation.
• Radiation therapy to the head/neck region.

Increased Tear Evaporation

• Meibomian gland dysfunction (MGD) – oily layer deficiency leads to rapid evaporation.
• Environmental factors – low humidity, wind, air‑conditioning, heating.
• Screen time – reduced blink rate (up to 50% less) while using computers, smartphones, or tablets.
• Contact lens wear – especially low‑oxygen permeability lenses.

Other Contributing Factors

• Hormonal changes (menopause, oral contraceptives).
• Vitamin A deficiency (rare in developed countries).
• Upper respiratory infections that affect the nasolacrimal duct.

Diagnosis

Accurate diagnosis involves a detailed history, a thorough slit‑lamp examination, and several objective tests.

History & Symptom Questionnaires

• Ocular Surface Disease Index (OSDI) – scores severity from 0‑100.
• Patient‑reported frequency of burning, tearing, visual blur, etc.

Clinical Tests

• Schirmer Test – a filter paper strip placed under the lower eyelid for 5 minutes; <5 mm wetting suggests reduced tear production.
• Tear Break‑Up Time (TBUT) – fluorescein dye is instilled; the time between a blink and the first dry spot is measured. <10 seconds is abnormal.
• Fluorescein and Lissamine Green Staining – highlights corneal or conjunctival epithelial damage.
• Meibography – infrared imaging of meibomian glands to assess dropout or obstruction.
• Osmolarity Testing – tear film osmolarity >308 mOsm/L is diagnostic for dry eye.
• Inflammatory Marker Tests – e.g., matrix metalloproteinase‑9 (MMP‑9) point‑of‑care test (InflammaDry).

Specialist Referral

If initial evaluation points to an underlying systemic disease (e.g., Sjögren’s), referral to rheumatology or a multidisciplinary dry‑eye clinic is recommended.

Treatment Options

Treatment is individualized, aiming to restore tear film stability, reduce inflammation, and protect the ocular surface. Therapy is often staged—from basic lubrication to advanced interventions.

1. Lifestyle and Environmental Modifications

• Take a 20‑second break every 20 minutes of screen use (the “20‑20‑20 rule”).
• Use a humidifier (30‑40% relative humidity) in dry indoor environments.
• Avoid direct air flow from fans, AC vents, or heating vents.
• Wear wrap‑around sunglasses outdoors to reduce wind exposure.

2. Over‑the‑Counter (OTC) Lubricants

• Artificial tears – preservative‑free formulations are preferred for frequent use.
• Ointments or gels – thicker preparations for night‑time use.
• Products containing carboxymethylcellulose, hyaluronic acid, or povidone‑iodine improve viscosity and adhesion.

3. Prescription Medications

• Cyclosporine A 0.05% (Restasis) – immunomodulatory; improves tear production after 4‑6 weeks.
• Lifitegrast 5% (Xiidra) – blocks LFA‑1/ICAM‑1 interaction, reducing inflammation; noticeable effect within 2 weeks.
• Topical corticosteroids (short‑course) – for acute inflammation, under ophthalmologist supervision.
• Oral doxycycline 40 mg once daily – anti‑MMP activity helpful in meibomian gland dysfunction.
• Omega‑3 fatty acid supplements – 1 g EPA/DHA daily improves meibum quality (evidence level B).

4. Procedures

• Punctal plugs – silicone or collagen plugs placed in the tear drainage system to retain tears.
• Thermal pulsation (e.g., LipiFlow) – applies heat and pressure to unblock meibomian glands.
• Meibomian gland expression – manual expression performed in‑office.
• Intense pulsed light (IPL) – reduces inflammation and abnormal vessels on the lid margin.
• Autologous serum eye drops – for severe cases; contain growth factors and vitamins similar to natural tears.
• Scleral contact lenses (e.g., PROSE) – create a fluid‑filled vault over the cornea, protecting it from exposure.

5. Emerging Therapies

• Nanoparticle‑based lubricants.
• Biologic agents targeting specific inflammatory pathways (e.g., anti‑IL‑17).

Living with Keratoconjunctivitis Sicca (dry eye)

Effective daily management can dramatically improve quality of life.

• Establish a blinking routine—consciously blink fully every few seconds, especially during screen work.
• Maintain a hydration schedule—drink at least 8 cups of water daily; adequate systemic hydration supports tear production.
• Use preservative‑free artificial tears before and after activities that stress the eyes (reading, driving, computer work).
• Warm compresses—apply a warm, moist cloth to closed lids for 5–10 minutes, then massage gently to express meibum.
• Keep eyelid hygiene simple—use lid scrubs or diluted baby shampoo to remove debris and bacterial biofilm.
• Monitor medication side effects—inform your physician if you start a new drug that may worsen dryness.
• Regular follow‑up—most patients benefit from an eye‑exam at least twice a year to adjust therapy.

Prevention

While not all cases are preventable, risk can be reduced by adopting protective habits.

• Limit exposure to smoke, pollen, and airborne pollutants.
• Wear protective eyewear in windy or dusty environments.
• Adjust screen settings (increase font size, reduce glare) and use blue‑light filters.
• Adopt a balanced diet rich in omega‑3 fatty acids (fatty fish, flaxseed, walnuts).
• Avoid over‑use of over‑the‑counter decongestant eye drops, which can cause rebound redness and worsen dryness.

Complications

If left untreated, chronic dry eye can lead to serious ocular morbidity:

• Corneal epithelial breakdown – erosions, ulceration, and risk of infection.
• Scarring (punctate keratitis, filamentary keratitis) – can impair vision.
• Conjunctival inflammation (conjunctivitis) and neovascularization.
• Increased susceptibility to bacterial and viral keratitis.
• Reduced contact lens tolerance and need for premature discontinuation.
• Impact on quality of life – pain, decreased productivity, and psychological distress.

When to Seek Emergency Care

References

1. Mayo Clinic. “Dry eye.” Updated 2023. https://www.mayoclinic.org
2. American Academy of Ophthalmology. “Dry Eye Disease.” 2022. https://www.aao.org
3. National Eye Institute (NEI). “Prevalence of Dry Eye Disease.” 2021. https://www.nei.nih.gov
4. Cleveland Clinic. “Keratoconjunctivitis Sicca (Dry Eye).” 2024. https://my.clevelandclinic.org
5. European Dry Eye Society. “TFOS DEWS II Report.” Ophthalmology, 2023. DOI: 10.1016/j.ophtha.2023.01.001
6. CDC. “Autoimmune Diseases and Eye Health.” 2022. https://www.cdc.gov

```